We are partnering with CSIRO’s Biomedical Manufacturing team to improve the capacity for Thai state-owned organisations to manufacture essential drugs to improve local and equitable access to medicines. This project will focus on training and development in two areas: 1) Biologic drug development using the Chinese Hamster Ovary (CHO) cell platform; and 2) Small molecule Active Pharmaceutical Ingredient (API) drug development using continuous flow processing. The team will conduct workshop-style and hands-on training at CSIRO’s state-of-the-art facilities in Clayton (National Vaccine and Therapeutics Laboratory, NVTL) by performing end-to-end process development work on two drugs selected by the Thai partners based on national priorities. Successful completion of this project will allow Thailand to transfer the knowledge, processes developed and apply the framework for industrialisation into the Thai biotech/manufacturing ecosystem for improved health outcomes and preparedness against health emergencies.
